Physician profile
Christopher Sek
NPI 1134606015
$8,274.78
in general payments reported to CMS, 2019-2025
30 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $638 · 2021: $755 · 2022: $1,382 · 2023: $1,342 · 2024: $1,746 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,328.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,197.91 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Allergan, INC. | $740.68 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $680.20 | 2019-2025 | Cequa |
| Biotissue Holdings INC. | $611.33 | 2022-2025 | |
| Alcon Vision LLC | $527.32 | 2020-2024 | Total30, Rocklatan, Simbrinza |
| Bausch & Lomb Americas INC. | $481.08 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $442.05 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $414.11 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $383.22 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $372.01 | 2019-2021 | |
| Harrow Eye, LLC | $322.31 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $316.93 | 2020-2023 | |
| Glaukos Corporation | $219.90 | 2022-2025 | Idosetr, Idose, Ce-Marked Kxla System |
| Tarsus Pharmaceuticals, INC. | $200.18 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $174.42 | 2022-2025 | Oxervate |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $174.04 | 2019-2025 | Eylea Hd, Eylea |
| Johnson & Johnson Surgical Vision, INC. | $137.68 | 2019-2025 | Tecnis Simplicity |
| Rxsight INC | $132.08 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $124.81 | 2024 | Acuvue |
| Carl Zeiss Meditec USA, INC. | $123.41 | 2023 | |
| Lkc Technologies, INC. | $119.20 | 2023 | |
| Astellas Pharma US INC | $97.43 | 2023-2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $66.60 | 2020-2023 | Acthar |
| Kala Pharmaceuticals, INC. | $63.95 | 2019-2021 | |
| Amgen INC. | $42.99 | 2025 | Tepezza |
| Shire North American Group INC | $32.63 | 2019 | |
| Biogen, INC. | $22.68 | 2022 | |
| Mallinckrodt Enterprises LLC | $19.99 | 2019 | |
| Rayner Intraocular Lenses Limited | $17.18 | 2022 | |
| Horizon Therapeutics Plc | $16.46 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.